# Shenzhen Burui Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-burui-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.breax.xyz
- Latest round: Series A (Feb 18, 2022)
- Investors on record: 2

## About

Based in Shenzhen, China and founded in 2019, Shenzhen Burui Biotechnology Co., Ltd operates as a screening and diagnosis solutions provider, focusing on breath detection and disease biomarker research. The company's CEO and founder, Mr. Alan Wang, who is responsible for directing all aspects of company strategy, planning, and operations. He had served as the vice president of 12 SIGMA Technologies, and the director of the surgical product department of Olympus China. The company has cooperated with many hospitals in medical research projects related to several serious diseases such as tuberculosis, lung cancer, and esophageal cancer. In January 2022, its Hunan production base has passed the GMP certification. In December 2019, its experimental product SCENT-I began testing samples for tuberculosis, lung cancer and esophageal cancer in collaboration with hospitals.

The company's product is composed of the hardware part of human exhaled breath detection mass spectrometer and the software part of artificial intelligence technology. It is a precise detection and analysis platform for the volatile organic compounds (VOCs) in human exhaled breath. The Scents A-3 is a single photon ionization-time of flight mass spectrometry (SPI-TOFMS), which can be used for online and real-time monitoring of VOCs at pptv level. It contains features such as low detection limit, high sensitivity, and controllable fragmentation.

## Funding rounds

- Series A, Feb 18, 2022 — Primavera Capital Group, Hangzhou Gaolue Investment Management

## Investors

- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series A
- Hangzhou Gaolue Investment Management — Series A